U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.30
    +0.48 (+0.57%)
     
  • Gold

    1,818.90
    +2.40 (+0.13%)
     
  • Silver

    23.03
    +0.12 (+0.51%)
     
  • EUR/USD

    1.1410
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3646
    -0.0033 (-0.24%)
     
  • USD/JPY

    114.6070
    +0.4070 (+0.36%)
     
  • BTC-USD

    42,133.29
    -1,072.49 (-2.48%)
     
  • CMC Crypto 200

    1,001.89
    -23.84 (-2.32%)
     
  • FTSE 100

    7,611.23
    +68.28 (+0.91%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Adagio Therapeutics (NASDAQ: ADGI) plans to file for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration for its COVID-19 antibody therapy in the second quarter of 2022. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Adagio might be too late to the party with this regulatory filing.